Skip to main content
NCBI home page
BMC Microbiology logoLink to BMC Microbiology
. 2026 Jan 16;26:172. doi: 10.1186/s12866-025-04676-z

Antibacterial activity and mechanism analysis of deoxycholic acid against Clostridium perfringens

Xinglong Song 1,2, Qingyun Guo 1,2, Zhenyu Zhong 1,2, Jiade Bai 1,2, Meihui Wang 1,2,3, Congshan Yang 4, Qingxun Zhang 1,2,✉
PMCID: PMC12947345  PMID: 41540343

Abstract

Background

Deoxycholic acid (DCA), a gut microbiota-derived secondary metabolite, exhibits broad-spectrum antimicrobial activity, particularly against Clostridium perfringens(C. perfringens). However, its specific antibacterial mechanism remains unclear.

Objective

To investigate the antibacterial activity and mechanism of DCA against C. perfringens, this study employed in vitro experiments combined with transcriptomic analysis to explore the inhibitory effects and underlying mechanism of DCA on C. perfringens.

Result

The results indicate that DCA can effectively inhibit the formation of C. perfringens biofilms, disrupt their cell walls, increase cell membrane permeability, and cause nucleic acid leakage. Transcriptome analysis revealed that DCA can up-regulating the oxidative phosphorylation pathway in C. perfringens and down-regulating antioxidant activity, peroxidase activity, and oxidoreductase activity, suggesting its potential antibacterial mechanism. This study provides insights into the antimicrobial activity of DCA and its mechanisms, laying a theoretical foundation for its development as a novel antimicrobial agent or feed additive.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12866-025-04676-z.

Keywords: Clostridium perfringens, Deoxycholic acid, Antimicrobial activity, Transcriptomics

Introduction

C. perfringens, a gram-positive anaerobic bacterium, is widely found in the intestinal microbiota of humans and animals, in water bodies, and in soil. It significantly impairs animal health and production performance, resulting in substantial annual economic losses to the global livestock industry [1–3]. Furthermore, C. perfringens is an important zoonotic pathogen. It not only endangers the health of animals but can also be transmitted to humans through contaminated food, leading to public health issues such as food poisoning. The Centers for Disease Control and Prevention, USA, reported that approximately 48 million Americans fall ill each year due to food poisoning caused by C. perfringens infection. In some developing and relatively poor countries, the public health risk posed by C. perfringens is even more serious [4, 5].

Treatment for C. perfringens infections typically involves antibiotics; however, C. perfringens has developed resistance to multiple antimicrobial agents, including chloramphenicol, lincosamides, tetracyclines, aminoglycosides, and macrolides [6–8]. Notably, β-lactams and oxazolamides are the drugs of choice for treating C. perfringens, but strains resistant to these drugs have now emerged [8, 9]. Plasmids have mediated the evolution and rapid adaptation of these drug-resistant strains, posing a major threat to veterinary health, food safety, and public health [10].Consequently, there is an urgent need to develop novel antimicrobial agents or antibacterial strategies to escalating issue of antimicrobial resistance in C. perfringens.

In recent years, the significant role of gut microbiota-derived metabolites in enhancing host health and regulating immune function has been widely confirmed. These metabolites, known as postbiotics, include exopolysaccharides (EPS), short chain fatty acids (SCFAs), bile acids (BAs), and other [11]. DCA is a secondary bile acid derived from the conversion of hepatocyte-synthesized primary bile acid by intestinal flora upon entering the intestine [12, 13]. While previous research on DCA primarily focused on its involvement in liver and gastrointestinal diseases [14, 15], recent studies have revealed its broad-spectrum antibacterial activity. DCA exhibits antimicrobial activity against pathogens such as Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, and C. perfringens. It can regulate the intestinal microbiota and alleviate the inflammatory response triggered by these pathogens, thereby making it a potential antimicrobial drug [16–19].

Studies have shown that DCA has a strong specific antibacterial effect on C.perfringens, and can alleviate necrotic enteritis in chickens caused by C. perfringens through multiple pathways, including attenuating inflammatory cyclooxygenase signaling and enhancing host defense peptide synthesis [19, 20]. However, its antibacterial mechanism of DCA remains incompletely understood. Considering the broad-spectrum antimicrobial properties of DCA, this study aims to systematically evaluate its in vitro antibacterial activity against C. perfringens and investigate the underlying antibacterial mechanisms. The research results are expected to provide theoretical reference for DCA as a new antibacterial agent against C. perfringens or as a feed additive in animal husbandry.

Materials and methods

Bacterial and antimicrobial agents

C. perfringens (CVCC2015) type A as an experimental strain. Bacteria were cultured using Tryptic Sulfite Cycloserine (TSC) agar and Fluid Thioglycollate Medium (FTG) under anaerobic conditions. DCA was purchased from Beijing Solarbio Technology Co., Ltd., purity > 99%.

Minimum inhibitory concentration (MIC) and Minimum bacterial concentration (MBC) of DCA against C. perfringens

The minimum inhibitory concentration (MIC) of DCA against C. perfringens was determined using the broth micro-dilution method in a 96-well plate. The MIC value was defined as the lowest concentration required to inhibit bacterial growth in the 96-well plate. At the MIC concentration, bacterial growth is inhibited but the bacteria are not killed in the culture medium. Subsequently, we spread the culture medium from the 96-well plate at concentrations above the MIC onto tryptic sulfate cycloserine (TSC) agar medium, and the concentration at which no bacterial growth was observed on the agar was defined as the MBC [21].

Effect of DCA on the growth curve of C. perfringens

C. perfringens was inoculated in FTG broth supplemented with DCA at concentrations of 1/4, 1/2 and 1 MIC, and the same volume of PBS was added to the control group. Bacteria were collected every hour to measure OD600nm. Each concentration treatment group was set up in three times.

Assessment of cell wall integrity and cell membrane permeability

Currently, alkaline phosphatase (AKP) and β-galactosidase (β-gal) have become important indicators for determining the integrity of bacterial cell walls and cell membranes [22, 23]. AKP is located between the bacterial cell wall and the cell membrane. Upon disruption of the cell wall, AKP is released into the extracellular environment [5]. Similarly, alterations in cell membrane permeability can be assessed by measuring the intracellular release of β-gal in C. perfringens. After 6 h of cultivation, the bacterial concentration was adjusted to an optical density (OD) of 0.5 at 600 nm. Subsequently, C. perfringens was exposed to different concentrations of DCA, with PBS serving as the negative control. After treatment, the supernatant was collected by centrifugation, and the levels of AKP and β-gal were measured to assess the extent of damage to the bacterial cell wall and membrane. At the same time, the concentration of dsDNA in the supernatant was measured using an ultra-micro ultraviolet spectrophotometer to observe the level of intracellular nucleic acid leakage.

Effect of DCA on the biofilm of C. perfringens

The impact of DCA on the biofilm formation of C. perfringens was assessed utilizing the crystal violet assay [24]. FTG broth, supplemented with varying concentrations of DCA, was aliquoted into 96-well microtiter plates, with each concentration being triplicated across three rows. Subsequently, C. perfringens was then inoculated into the wells and incubated overnight to facilitate biofilm formation. Following incubation, the bacterial suspension in the wells was removed, and the plates were gently washed twice with PBS to remove non-adherent bacteria and residual culture medium. After drying, 100 µL of anhydrous methanol was added to each well to fix the biofilm for 15 min. Subsequently, 200 µL of 1% crystal violet solution was applied to stain the wells for 30 min. Then wash the plate with PBS and dissolve the biofilm with 33% glacial acetic acid for 10 min. Finally, the absorbance at OD570nm was measured. The absorbance value was directly proportional to the biofilm mass, thereby reflecting the effect of DCA on the formation of C. perfringens biofilm.

Transmission electron microscopy (TEM) and Scanning electron microscopy (SEM) inspection

The concentration of C. perfringens cultured for 6 h was adjusted to OD600nm of 0.5. The bacterial precipitate was subsequently inoculated with DCA solution at concentrations of 0, 1 MIC and 8 MIC, and co-cultured for 2 h at 37 °C. Following incubation, the bacteria were collected by centrifugation, gently rinsed with PBS, and the PBS was discarded. The 2.5% glutaraldehyde electron microscopy fixative was added, and the bacteria were resuspended in the fixative for two hours at room temperature. The samples were processed according to a previously published protocol and subsequently examined using TEM and SEM [25, 26].

Total RNA extraction and RNA sequencing

Four independent samples of the DCA-treated group (1 MIC) and the control group of C. perfringens were cultured for 6 h at 37 °C. Total RNA was extracted from bacterial precipitates, and the extracted RNA was quality assessed to ensure its integrity, concentration, and purity. Libraries were constructed using the TruSeq™ Stranded Total RNA Library Prep Kit with rRNA depletion. NovaSeqXPlus sequencing platform (ShangHai majorbio Bio-pharm technology Co.,ltd) was used for mRNA sequencing.

Analysis of differentially expressed genes

The EBSeq algorithm was used to screen the differentially expressed genes, and the criteria for screening were Fold Change (FC) greater than 1.5 and FDR < 0.05. The differentially expressed genes were annotated in the GO (Gene Ontology) database and KEGG (Kyoto Encyclopedia of Genes and Genomes) database, and the enrichment analysis was carried out; the significance levels of the GO and KEGG Pathways enriched with differentially expressed genes were analysed by the Fisher exact test based on the hypergeometric distribution. KEGG Pathway significance levels, and screened out the GO items and metabolic pathways that were significantly enriched for differentially expressed genes.

qPCR for Detection of Gene Expression

For validation of transcriptional profiling from RNA-Seq, quantitative real-time PCR (qRT-PCR) was performed. Total RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara, Japan). qPCR was performed with ChamQ SYBR qPCR Master Mix (High ROX Premixed) (Vazyme, Nanjing, China). Primers for qPCR were obtained by querying the gene database at NCBI and were synthesized by Bioengineering Biotechnology Co. (Bioengineering Biotechnology, Shanghai, China). The relative expression level of genes was represented by 2^(-∆∆Ct), and 16sRNA was used as a reference gene [22]. The primer details are shown in Supplementary Table S1.

Statistical analysis

All the experimental data were replicated three times or more, statistically analyzed by SPSS Statistics 26.0, and plotted by GraphPad Prism 9.0. The results of the experiments were expressed as the ‘mean ± standard deviation’, and the t-test was used to compare the differences between the groups, with * representing a significant difference (p < 0.05) and ** representing a highly significant difference (p < 0.01).

Result

Effect of DCA on the growth curve and biofilm of C. perfringens

The results showed that DCA had a strong inhibitory effect on C. perfringens with a MIC value of 0.125 mg/mL and MBC value of 1 mg/mL (8 MIC). As is shown in Fig. 1A, when the DCA concentration is 1/4 MIC and 1/2 MIC, it can significantly inhibit the growth of C. perfringens. When the concentration is 1 MIC, DCA can completely inhibit the growth of C. perfringens. As is shown in Fig. 1B, the results of the crystal violet assay showed that DCA at concentrations ranging from 1/4 MIC to 1 MIC significantly inhibited the formation of C. perfringens biofilm in a concentration-dependent manner compared with the control group.

Fig. 1.

Fig. 1

Open in a new tab

The inhibitory effect of DCA on the growth and biofilm formation of C. perfringens. A Effect of different concentrations of DCA on the growth curve of C. perfringens. B Effect of DCA on biofilm formation of C. perfringens, OD570nm indicates biofilm content

Effect of DCA on the membrane integrity of C. perfringens cell walls

From the detection of AKP and β-gal content (Fig. 2A, Fig. 2C), DCA can destroy the integrity of cell walls and the permeability of cell membranes, and this destructive ability is proportional to the concentration of DCA. As shown in Fig. 2B, the concentration of extracellular dsDNA significantly increased after DCA treatment, indicating that DCA can alter cell membrane permeability, leading to nucleic acid leakage, which may have a negative impact on maintaining normal bacterial physiological functions.

Fig. 2.

Fig. 2

Open in a new tab

The effect of DCA on the cell membrane permeability and cell wall integrity of C. perfringens. A Extracellular AKP content in C. perfringens after treatment with different concentrations of DCA, a value that indirectly reflects cell wall integrity. B Extracellular DNA concentration of C. perfringens after treatment with different concentrations of DCA. C Effect of different concentrations of DCA treatment on cell membrane integrity of C. perfringens, OD410 nm represents extracellular β-Gal content, and higher values indicate more severe cell membrane disruption

Effect of DCA on C. perfringens morphology

TEM and SEM further showed the disruptive effect of DCA on the structure of C. perfringens. As can be seen in Fig. 3 and Fig. 4, the untreated cells (control) showed a typical C. perfringens ultrastructure, with the cell membrane, cell wall and no cellular damage was observed. After treatment with MIC concentration of DCA for 2 h, some of the cell edges were blurred and the surface of the cell wall appeared wrinkled. Under the treatment with MBC concentration of DCA, the cell wall membrane was completely blurred and the bacterial surface showed a large number of breaks and was no longer intact. The results showed that low concentrations of DCA had a certain destructive effect on the cell membrane and cell wall of C. perfringens, while at the concentration of MBC, DCA could directly destroy the cell structure of C. perfringens leading to the death of the bacteria.

Fig. 3.

Fig. 3

Open in a new tab

TEM micrographs of C. perfringens treated with DCA

Fig. 4.

Fig. 4

Open in a new tab

SEM micrographs of C. perfringens treated with DCA at the MIC/MBC (8MIC) and control cells without treatment

Analysis of differentially expressed genes (DEGs)

Transcriptomics analysis was used to understand the gene expression changes between DCA-treated and untreated groups. A total of 659 DEGs were identified compared to the control group of these, 355 were up-regulated and 304 were down-regulated (Fig. 5A). Details of the DEGs are shown in Supplementary Table S2.

Fig. 5.

Fig. 5

Open in a new tab

Overview of the gene expression analysis. A Volcano mapping of differentially expressed genes (DEGs) based on RNA-seq analysis of C. perfringens after untreated and DCA treatment. B Principal component analysis (PCA) of C. perfringens gene expression in the DCA treated and control groups. C Hierarchical clustering heat map of different gene expressions in different experimental conditions. Red represents high gene expression and blue represents low gene expression. D Comparison of fold changes in DEGs between RNA-seq and RT-PCR methods

To further explore the effect of DCA on C. perfringens, the differentially expressed genes were subjected to GO functional gene enrichment analysis. As seen in Fig. 6A, GO enrichment results showed that 202 GO terms were up-regulation, mainly involving protein-containing complex, ribonucleoprotein complex, structural constituent of ribosome and structural molecule activity. The down-regulated GO terms are enriched in molecular function, specifically enriched in four GO terms: antioxidant activity, peroxidase activity, oxidoreductase activity and protein serine/threonine kinase activity(Fig. 6B). While Details of GO enrichment of DEGs are shown in Supplementary Table S3.

Fig. 6.

Fig. 6

Open in a new tab

DEGs KEGG and GO enrichment ranking results. A GO enrichment analysis of up-regulated genes in C. perfringens after DCA treatment. B GO enrichment analysis of down-regulated genes in C. perfringens after DCA treatment. C KEGG enrichment analysis of up-regulated genes in C. perfringens after DCA treatment. D KEGG enrichment analysis of down-regulated genes in C. perfringens after DCA treatment

The differentially expressed genes of C. perfringens after DCA were subjected to KEGG enrichment analysis, and as shown in Fig. 6C, after DCA treatment, up-regulated genes were enriched in four pathways: Ribosome, oxidative phosphorylation, pyruvate metabolism and taurine and hypotaurine metabolism. Down-regulated genes were enriched in pathways that did not show significant differences (Fig. 6D). See Supplementary Table S4 for details.

Discussion

The spores of C. perfringens exhibit strong environmental resistance, capable of withstanding extreme conditions such as high temperatures and dryness, and demonstrate significant resistance to conventional chemical disinfectants [27]. Additionally, with the widespread use of antibiotics, this strain has gradually evolved to develop multidrug resistance. To reduce antibiotic use and mitigate the threat that C. perfringens poses to public health, the development of novel antimicrobial agents to address C. perfringens infections has become an urgent research priority. Currently, there is very little research on non-antibiotic antimicrobial drugs for C. perfringens. Zheng et al. studied the antibacterial activity of natural propolis and identified caffeic acid as its primary component against C. perfringens, concluding that propolis could serve as an alternative to antibiotics [5]. DCA was proposed in 2019 as a potential treatment for necrotic enteritis (NE) caused by C. perfringens in chickens [20]. Subsequently, Kim et al. conducted further research and found that DCA can induce the production of host defense peptides to alleviate NE, further revealing the potential of DCA as an antibiotic alternative [19]. However, these two studies focused on the effects of DCA on the host, and there have been no studies on how DCA acts on C. perfringens. Therefore, the aim of our study was to reveal the antibacterial activity and mechanism of DCA against C. perfringens.

By detecting AKP and β-gal activity, we can observe that DCA can disrupt the cell wall and cell membrane structure of C. perfringens. To validate these results, we directly observed the cellular structure using SEM and TEM. The control group of C. perfringens exhibited a thick, mature, and dense three-dimensional structure. At a DCA concentration of 1 MIC, the cell wall already showed significant wrinkling and deformation, and at an 8 MIC concentration, the cells began to rupture, with intracellular material leaking out, indicating that DCA can effectively disrupt the cellular structure of C. perfringens.

The virulence and drug resistance of C.perfringens are closely related to the formation of biofilms, which can prevent or delay the penetration of antibiotics and allow them to escape the killing effect of antimicrobial drugs [28]. As can be seen from Fig. 1D, DCA can significantly inhibit the formation of C. perfringens biofilms, and transcriptomic results indicated that DCA treatment significantly down-regulated the expression of the spoVG gene in C. perfringens (log2FC = −3.00). The spovG gene is widely present in bacteria and has been confirmed to be a key regulatory factor in biofilm formation in bacteria such as Bacillus subtilis, Listeria monocytogenes, Staphylococcus aureus, Bacillus cereus, and Staphylococcus epidermidis [28–30]. However, whether the spoVG gene can regulate the formation of C. perfringens biofilms has not yet been confirmed and requires further research.

Among the DEGs, def gene was significantly down-regulated(log2FC = −3.52), the down-regulation of this gene was also verified by qPCR(RS09240). The def gene encodes peptide deformylase (PDF), an enzyme whose core function is to catalyze the removal of the formyl group (-CHO) from the N-terminal formylmethionine of newly synthesized polypeptide chains, thereby forming methionine. This is an important step in post-translational modification of bacterial proteins. If PDF is inhibited, it leads to the accumulation of un-deformylated proteins, resulting in bacterial growth arrest or death [31–33]. Current, PDF has become an important target for the development of new antimicrobial drugs [34, 35]. This indicates that DCA may inhibit bacterial protein synthesis by down-regulating the def gene, thereby exerting an antibacterial effect against C. perfringens.

Transcriptomics is important for understanding the antibacterial mechanism of DCA. KEGG enrichment results showed that the oxidative phosphorylation pathway was significantly enriched. Oxidative phosphorylation is the main pathway for ATP production in bacteria, and up-regulation of this pathway promotes the activity of the bacterial electron transport chain; however, the high activity of the ETC may lead to electron leakage, which reacts with oxygen to generate large amounts of reactive oxygen species (ROS), such as superoxide anions and hydrogen peroxide [36]. GO enrichment analysis showed that antioxidant activity, peroxidase activity and oxidoreductase activity were down-regulated in C. perfringens. These enzymes are normally responsible for scavenging ROS from the cell, and if the activity of these enzymes is reduced, the ability of the bacteria to process ROS is diminished, leading to ROS accumulation [37, 38]. This indicates that DCA exerts its antibacterial effect by disrupting the redox balance of C. perfringens. However, whether DCA can induce ROS and lead to oxidative damage in C. perfringens requires further investigation.

This study preliminarily investigated the antibacterial activity of DCA against C. perfringens and its potential mechanisms, but several limitations remain. First, transcriptome data reflect changes at the transcriptional level, which do not fully correspond to alterations in protein expression levels. Subsequent studies should integrate proteomics or metabolomics technologies to further validate the expression and modification status of relevant functional proteins. Second, although the study found that DCA up-regulates the oxidative phosphorylation pathway and down-regulates the expression of antioxidant-related genes in C. perfringens, its specific regulatory mechanism remains unclear and requires further investigation.

Conclusions

In conclusion, DCA exhibits potent antibacterial activity against C. perfringens, effectively inhibiting biofilm formation, disrupting bacterial cell wall integrity, and increasing membrane permeability. Transcriptome results indicate that DCA can up-regulate the oxidative phosphorylation pathway in C. perfringens and down-regulate antioxidant activity, peroxidase activity, and oxidoreductase activity, suggesting this may represent its potential antibacterial mechanism.

Supplementary Information

Supplementary Material 1. (23.5KB, csv)
Supplementary Material 2. (833.7KB, csv)
Supplementary Material 3. (14.8KB, csv)
Supplementary Material 4. (10.3KB, csv)

Acknowledgements

We sincerely thank the Beijing Milu Ecological research Center, China Agricultural University, and Anhui Agricultural University for providing the experimental conditions. We would like to express our gratitude to all personnel involved in this experiment. All authors participated in the critical review of the manuscript; gave final approval for the version to be published; agreed to submit the manuscript to the journal; and agreed to take responsibility for all aspects of the work.

Authors’ contributions

X.-L.S. conducted the experiment and wrote the main manuscript. Z.-Y.Z., J.-D.B., and Q.-Y.G. carried out the analysis and reviewed the final manuscript, M.-H.W. contributed to reviewing the final manuscript, C.-S.Y. conducted the laboratory analysis. Q.-X.Z. designed the experiment and revised the manuscript.

Funding

This work was supported by the Financial Program of BJAST (25CA005).

Data availability

The datasets generated and analyzed during the present study can be obtained from the first author upon reasonable request. The raw sequencing data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA) under BioProject accession number PRJNA1314926.（https://dataview.ncbi.nlm.nih.gov/?search = SUB15589106&archive = bioproject）. Other data are provided in the supplementary information file.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Uzal FA, Navarro MA, Asin J, Boix O, Ballarà-Rodriguez I, Gibert X. Clostridial diarrheas in piglets: a review. Vet Microbiol. 2023;280:109691. 10.1016/j.vetmic.2023.109691. [DOI] [PubMed] [Google Scholar]
  • 2.Alizadeh M, Shojadoost B, Boodhoo N, Astill J, Taha-Abdelaziz K, Hodgins DC, et al. Necrotic enteritis in chickens: a review of pathogenesis, immune responses and prevention, focusing on probiotics and vaccination. Anim Health Res Rev. 2021;22:147–62. 10.1017/S146625232100013X. [DOI] [PubMed] [Google Scholar]
  • 3.Mwangi S, Timmons J, Fitz-coy S, Parveen S. Characterization of Clostridium perfringens recovered from broiler chicken affected by necrotic enteritis. Poult Sci. 2019;98:128–35. 10.3382/ps/pey332. [DOI] [PubMed] [Google Scholar]
  • 4.Johnson S, Skinner AM, Lostutter C, Duke T, Posthaus H. Enteritis necroticans and Clostridium perfringens type C; epidemiological and pathological findings over the past 20 years. PLoS Negl Trop Dis. 2025;19:e0012836. 10.1371/journal.pntd.0012836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Zheng X, Al Naggar Y, Wu Y, Liu D, Hu Y, Wang K, et al. Untargeted metabolomics description of propolis’s in vitro antibacterial mechanisms against Clostridium perfringens. Food Chem. 2023;406:135061. 10.1016/j.foodchem.2022.135061. [DOI] [PubMed] [Google Scholar]
  • 6.Adams V, Han X, Lyras D, Rood JI. Antibiotic resistance plasmids and mobile genetic elements of Clostridium perfringens. Plasmid. 2018;99:32–9. 10.1016/j.plasmid.2018.07.002. [DOI] [PubMed] [Google Scholar]
  • 7.Fayez M, Elsohaby I, Al-Marri T, Zidan K, Aldoweriej A, El-Sergany E, et al. Genotyping and antimicrobial susceptibility of Clostridium perfringens isolated from dromedary camels, pastures and herders. Comp Immunol Microbiol Infect Dis. 2020;70. 10.1016/j.cimid.2020.101460. [DOI] [PubMed]
  • 8.Wu K, Li Z, Fang M, Yuan Y, Fox EM, Liu Y, et al. Genome characteristics of the optrA-positive Clostridium perfringens strain QHY-2 carrying a novel plasmid type. mSystems. 2023. 10.1128/msystems.00535-23. [DOI] [PMC free article] [PubMed]
  • 9.Gulliver EL, Adams V, Marcelino VR, Gould J, Rutten EL, Powell DR, et al. Extensive genome analysis identifies novel plasmid families in Clostridium perfringens. Microb Genom. 2023;9. 10.1099/mgen.0.000995. [DOI] [PMC free article] [PubMed]
  • 10.Feng Y, Fan X, Zhu L, Yang X, Liu Y, Gao S, et al. Phylogenetic and genomic analysis reveals high genomic openness and genetic diversity of Clostridium perfringens. Microb Genom. 2020;6:1–15. 10.1099/mgen.0.000441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu C, Ma N, Feng Y, Zhou M, Li H, Zhang X, et al. From probiotics to postbiotics: concepts and applications. Animal Research and One Health. 2023;1:92–114. 10.1002/aro2.7. [Google Scholar]
  • 12.Jin D, Huang K, Xu M, Hua H, Ye F, Yan J, et al. Deoxycholic acid induces gastric intestinal metaplasia by activating STAT3 signaling and disturbing gastric bile acids metabolism and microbiota. Gut Microbes. 2022;14. 10.1080/19490976.2022.2120744. [DOI] [PMC free article] [PubMed]
  • 13.Wahlström A, Brumbaugh A, Sjöland W, Olsson L, Wu H, Henricsson M, et al. Production of deoxycholic acid by low-abundant microbial species is associated with impaired glucose metabolism. Nat Commun. 2024;15:4276. 10.1038/s41467-024-48543-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sato Y, Kobayashi M, Ohira M, Funayama R, Maekawa M, Karasawa H, et al. Downregulation of ABCC3 activates MAPK signaling through accumulation of deoxycholic acid in colorectal cancer cells. Cancer Sci. 2024;115:1778–90. 10.1111/cas.16132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tanaka M, Nakura H, Tateishi T, Watanabe M, Nakaya S, Kumai T, et al. Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury. J Hepatol. 1999;31:263–70. 10.1016/S0168-8278(99)80223-2. [DOI] [PubMed] [Google Scholar]
  • 16.Zheng Y, Yue C, Zhang H, Chen H, Liu Y, Li J. Deoxycholic Acid and Lithocholic Acid Alleviate Liver Injury and Inflammation in Mice with Klebsiella pneumoniae-Induced Liver Abscess and Bacteremia. J Inflamm Res. 2021;14:777–89. 10.2147/JIR.S298495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vidal JE, Wier MN, A. Angulo-Zamudio U, McDevitt E, Jop Vidal AG, Alibayov B, et al. Prophylactic Inhibition of Colonization by Streptococcus pneumoniae with the Secondary Bile Acid Metabolite Deoxycholic Acid. Infect Immun. 2021;89. 10.1128/IAI.00463-21. [DOI] [PMC free article] [PubMed]
  • 18.Zhao W, Wang J, Li X, Li Y, Ye C. Deoxycholic acid inhibits Staphylococcus aureus-induced endometritis through regulating TGR5/PKA/NF-κB signaling pathway. Int Immunopharmacol. 2023;118:110004. 10.1016/j.intimp.2023.110004. [DOI] [PubMed] [Google Scholar]
  • 19.Kim DM, Liu J, Whitmore MA, Tobin I, Zhao Z, Zhang G. Two intestinal microbiota-derived metabolites, deoxycholic acid and butyrate, synergize to enhance host defense peptide synthesis and alleviate necrotic enteritis. J Anim Sci Biotechnol. 2024;15:29. 10.1186/s40104-024-00995-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wang H, Latorre JD, Bansal M, Abraha M, Al-Rubaye B, Tellez-Isaias G, et al. Microbial metabolite deoxycholic acid controls Clostridium perfringens-induced chicken necrotic enteritis through attenuating inflammatory cyclooxygenase signaling. Sci Rep. 2019;9:14541. 10.1038/s41598-019-51104-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li J, Li C, Shi C, Aliakbarlu J, Cui H, Lin L. Antibacterial mechanisms of clove essential oil against Staphylococcus aureus and its application in pork. Int J Food Microbiol. 2022;380:109864. 10.1016/j.ijfoodmicro.2022.109864. [DOI] [PubMed] [Google Scholar]
  • 22.Xin J, Pu Q, Wang R, Gu Y, He L, Du X, et al. Antibacterial activity and mechanism of chelerythrine against Streptococcus agalactiae. Front Vet Sci. 2024;11. 10.3389/fvets.2024.1408376. [DOI] [PMC free article] [PubMed]
  • 23.Yu Y, Dong J, Wang Y, Gong X. RNA-seq analysis of antibacterial mechanism of Cinnamomum camphora essential oil against Escherichia coli. PeerJ. 2021;9:e11081. 10.7717/peerj.11081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bai B, Wang M, Zhang Z, Guo Q, Yao J. Mechanistic investigation of the pyrolysis temperature of reed wood vinegar for maximising the antibacterial activity of Escherichia coli and its inhibitory activity. Biology. 2024;13:912. 10.3390/biology13110912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Liu X, Shu Q, Chen Q, Pang X, Wu Y, Zhou W, et al. Antibacterial efficacy and mechanism of Mannosylerythritol lipids-A on Listeria monocytogenes. Molecules. 2020;25:4857. 10.3390/molecules25204857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rao W, Fang Z, Chen Z, Wu J, Fang X. Antibacterial mechanism of metabolites of Leuconostoc mesenteroides against Serratia liquefaciens. LWT. 2023;187:115335. 10.1016/j.lwt.2023.115335. [Google Scholar]
  • 27.Lindström M, Heikinheimo A, Lahti P, Korkeala H. Novel insights into the epidemiology of Clostridium perfringens type A food poisoning. Food Microbiol. 2011;28:192–8. 10.1016/j.fm.2010.03.020. [DOI] [PubMed] [Google Scholar]
  • 28.Hu WS, Woo DU, Kang YJ, Koo OK. Biofilm and spore formation of Clostridium perfringens and its resistance to disinfectant and oxidative stress. Antibiotics. 2021;10:396. 10.3390/antibiotics10040396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Shi C, Zheng L, Lu Z, Zhang X, Bie X. The global regulator SpoVG regulates Listeria monocytogenes biofilm formation. Microb Pathog. 2023;180:106144. 10.1016/j.micpath.2023.106144. [DOI] [PubMed] [Google Scholar]
  • 30.Huang Q, Zhang Z, Liu Q, Liu F, Liu Y, Zhang J, et al. SpoVG is an important regulator of sporulation and affects biofilm formation by regulating Spo0A transcription in Bacillus cereus 0–9. BMC Microbiol. 2021;21(1):172. 10.1186/s12866-021-02239-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sangshetti J, Khan FA, Shinde D. Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2014;22:214–36. 10.2174/0929867321666140826115734. [DOI] [PubMed] [Google Scholar]
  • 32.Merzoug A, Chikhi A, Bensegueni A, Boucherit H, Okay S. Virtual Screening Approach of Bacterial Peptide Deformylase Inhibitors Results in New Antibiotics. Mol Inform. 2018;37. 10.1002/minf.201700087 [DOI] [PubMed]
  • 33.Gokhale KM, Telvekar VN. Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis. Chem Biol Drug Des. 2021;97:148–56. 10.1111/cbdd.13769. [DOI] [PubMed] [Google Scholar]
  • 34.Singhal A, Fang FC. Direct and indirect inhibition of Salmonella peptide deformylase by nitric oxide. MBio. 2020. 10.1128/mBio.01383-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Merzoug A, Chikhi A, Bensegueni A, Boucherit H, Okay S. Virtual Screening Approach of Bacterial Peptide Deformylase Inhibitors Results in New Antibiotics. Mol Inform. 2018;37. 10.1002/minf.201700087. [DOI] [PubMed]
  • 36.Imlay JA. Pathways of oxidative damage. Annu Rev Microbiol. 2003;57:395–418. 10.1146/annurev.micro.57.030502.090938. [DOI] [PubMed] [Google Scholar]
  • 37.Imlay JA. Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem. 2008;77:755–76. 10.1146/annurev.biochem.77.061606.161055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ezraty B, Gennaris A, Barras F, Collet J-F. Oxidative stress, protein damage and repair in bacteria. Nat Rev Microbiol. 2017;15:385–96. 10.1038/nrmicro.2017.26. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1. (23.5KB, csv)
Supplementary Material 2. (833.7KB, csv)
Supplementary Material 3. (14.8KB, csv)
Supplementary Material 4. (10.3KB, csv)

Data Availability Statement

The datasets generated and analyzed during the present study can be obtained from the first author upon reasonable request. The raw sequencing data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA) under BioProject accession number PRJNA1314926.（https://dataview.ncbi.nlm.nih.gov/?search = SUB15589106&archive = bioproject）. Other data are provided in the supplementary information file.

Articles from BMC Microbiology are provided here courtesy of BMC

RESOURCES